BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
Neuroscience
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance...
BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma
BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma Amsterdam, The Netherlands, 17 November 2022 - BioGeneration Ventures...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapyMALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE)...
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company,...
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the...
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the...
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint...
Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference
KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"),...
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc....
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
Conference Call and Webcast at 5:00pm ET on November 14, 2022, Following the Oral PresentationTHE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE...
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the...
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™
Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression PatientsBURLINGTON, Mass. and JERUSALEM, Nov. 03, 2022...
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development...
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 YearsBURLINGTON, Mass. and JERUSALEM, Nov. 01,...
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental healthMALVERN, Pa., Oct. 31, 2022...
Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective AgonistTOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei...
Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
5th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston, MA on October 31st Neuroscience 2022 by the Society of...